Queen Camilla's ‘Health Issues' Revealed After King Charles' Cancer Found ‘Incurable'—She's on ‘Her Last Legs'
A lot of the conversation about the British Royal family in the last few years has been about the health of different members of the family. Sure, the feuds take a lot of the attention, but it's impossible to ignore that the health of various members of the royal family has been under scrutiny lately. This includes King Charles, who has cancer and is reportedly very sick, and Kate Middleton, who was diagnosed with cancer as well, and who is now cancer-free.
Health speculation now includes Queen Camilla, too. The Queen is reportedly not doing very well, with a source telling RadarOnline, 'Camilla really is on her last legs – literally. Along with all her other health issues, she can now hardly walk.'
More from StyleCaster
Trump Accused of Stealing King Charles' Thunder After the Royal Made a Clear Stance Against the President
Prince William Faces Devastating News After King Charles' Cancer Found 'Incurable'
Related: See what Queen Camilla looked like throughout the years
The source explained her issues in detail and what is being done to manage them. 'She gets these Sole Bliss shoes made by a company in London shipped into the palace by the truckload as she is trying to cover up her feet deformities on royal engagements. She has the shoes hand-tooled to cover up the bony looking growths on the sides of her feet and totters around in them trying to pretend like there's nothing wrong.'
However, the source also added that 'sooner or later she could be headed for a wheelchair – if she lives much longer,' explaining that 'Her spending on medics and specialists is through the roof as she's too vain to admit she needs a wheelchair.' Reportedly, the Queen has been warned against painful surgery to remove bunions.
The outlet also reports the Palace has hidden the Queen's ailments for a while, as she reportedly had to have surgery for a pickled liver due to her decades of drinking years ago. She also recently had pneumonia. However, it seems now the stress of her husband's illness and the desire not to appear crippled in public are putting great strain on her.
All of this comes amid reports that King Charles' cancer is reportedly incurable, but manageable, according to royal writer and associate editor of the Daily Telegraph, Camilla Tominey. 'The talk now is that he may die 'with' cancer, but not 'of' cancer following a rigorous treatment program,' she wrote.
Tominey also said that planning for Charles' 80th birthday in 2028, while 'very tentative,' is going ahead. Not just that, there are reportedly plans for King Charles and his son, Prince Harry, to reunite publicly at the Invictus Games in Birmingham in 2027. 'There is an awareness that the impasse cannot continue forever, not least if it starts to reflect badly on the king.'
Prince Harry recently spoke of his desire to reconcile with his father, referencing his illness specifically, and indicating that he didn't know how long his father had left. The hope would be that the reunion would also include Prince Harry's kids.
However, it looks like there are plenty of health concerns in the royal family, and right now, there's very little anyone can do but see how things develop.
Best of StyleCaster
The 26 Best Romantic Comedies to Watch if You Want to Know What Love Feels Like
These 'Bachelor' Secrets & Rules Prove What Happens Behind the Scenes Is So Much Juicier
BTS's 7 Members Were Discovered in the Most Unconventional Ways
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
'Forever chemical' found in all but one of tested UK rivers
A chemical that scientists worry might have an impact on human reproduction has been found in rivers across the UK. Researchers from York University analysed samples from 32 rivers in all the UK's 4 nations and found traces of trifluoroacetic acid (TFA) at 98% of the test locations. TFA is what's known as a "forever chemical" which means that it breaks down extremely slowly in nature, and so accumulates over time. As with other "forever chemicals", also known as PFAS, just how much a threat to human health and at what concentrations is still being researched. But scientists in Germany say having looked at the impact of TFA on animals they want it to be classed as toxic for reproduction. TFA forms when synthetic chemicals from other "forever chemicals" such as those found in pesticides and refrigerants are partially broken down. "This molecule (TFA) is everywhere," Alistair Boxall, professor of Environmental Science at the University of York who carried out the research, told the BBC. "We will all be drinking water containing TFA every day - so we'll be exposed throughout our lifetime. It's that long-term, low level exposure that is the big concern." This new study was funded by environmental charity Fidras and involved sampling in 5 rivers in Wales, 3 in Northern Ireland 14 in Scotland and 10 in the north of England. The highest concentration was recorded on the River Kelvin in Glasgow. The River Ness, which flows from Loch Ness to the Moray Firth, was the only river sampled not to show traces of TFA. Recent studies in the EU have found TFA to be widespread, including in wine and food, human blood and breast milk. Authorities in Germany have been looking with interest at rising TFA levels in drinking water. In the last two decades its concentrations have gone up fourfold and researchers have been trying to establish what impact - if any - it might have on human health. Citing scientific studies that showed TFA affecting rabbit and rat foetuses, the German Federal Environment Agency (UBA) has applied to the European Chemicals Agency (ECHA) for TFA to be classified as toxic for reproduction and harmful to the environment. That could eventually lead to recommendations being made in the EU as to how products containing TFA should be controlled. "Currently, there are no expected adverse health effects from consuming water or food contaminated with TFA," said Andreas Hensel, president of the German Federal Institute for Risk Assessment (BfR). "The new classification is an important step in preparing further measures to ensure that this remains the case in the future". There aren't currently any rules or regulations in place to identify or reduce the concentrations of TFA either in the environment or in drinking water supplies in the UK. But aware of concerns, the Drinking Water Inspectorate, which monitors and regulates drinking water quality in England and Wales, has just commissioned its own research. It will look at how much TFA is already in drinking water and what risk - if any - it poses. "The information signposted by the University of York suggests that TFA can be formed from the degradation of PFAS-containing pesticides," Ann Bunting, Principal Inspector of the Drinking Water Inspectorate, told the BBC. "It is important that the fate of pesticides and other chemicals in the environment is understood, in order to protect drinking water sources." A spokesperson for Water UK, which represents the UK's water companies, told the BBC: "We want to see PFAS, including TFA, banned and the development of a national plan to remove it from the environment which should be paid for by manufacturers." Warning over 'dirty secret' of toxic chemicals on farmers' fields 'Forever chemicals' limited in US tap water Toughen 'forever chemical' water rules - experts
Yahoo
41 minutes ago
- Yahoo
‘Milestone' treatment could reshape future leukaemia care
A UK trial has found that a chemotherapy-free approach to treatment may lead to better outcomes for some leukaemia patients, in what scientists are calling a "milestone". The groundbreaking UK-wide trial could reshape the way the most common form of leukaemia in adults is treated. Researchers from Leeds assessed whether two targeted cancer drugs could perform better than standard chemotherapy among patients with chronic lymphocytic leukaemia (CLL). Chronic lymphocytic leukaemia is the most common form of leukaemia in adults, with about 4,000 new cases recorded in the UK every year. The Flair trial, which took place at 96 cancer centres across the UK, saw 786 people with previously untreated CLL randomly assigned to receive standard chemotherapy; a single targeted drug, ibrutinib, or two targeted drugs taken together, ibrutinib and venetoclax, with treatment guided by personalised blood tests. Researchers found that after five years, 94 per cent of patients who received ibrutinib plus venetoclax were alive with no disease progression. This compares with 79 per cent for those on ibrutinib alone and 58 per cent for those on standard chemotherapy, according to the study, which has been published in the New England Journal of Medicine and presented to the European Haematology Association congress in Milan, Italy. Meanwhile, 66 per cent of patients on the new combination had no detectable cancer in their bone marrow after two years, compared with none of the people who received ibrutinib alone and 48 per cent on chemotherapy. Ibrutinib is a type of drug known as a cancer growth blocker, which works by stopping signals that cancer cells use to divide and grow, and venetoclax blocks the functions of a protein found in CLL cells. Experts said that the new treatment regime was also tolerated better than traditional treatments. Dr Talha Munir, consultant haematologist at Leeds Teaching Hospitals NHS Trust, who led the study, said the Flair trial is a 'milestone'. 'We have shown that a chemotherapy-free approach can be not only more effective but also more tolerable for patients,' she said. 'By tailoring individualised treatment based on how well the cancer responds, we're moving into an era of truly personalised medicine.' Catherine Whitfield, 63, from Farnley, West Yorkshire, was diagnosed with CLL in 2018 after she noticed symptoms including bleeding gums, constant illness and neck pain. She signed up for the trial, which was coordinated by the Leeds Cancer Research UK Clinical Trials Unit at the University of Leeds and sponsored by the University of Leeds. 'After three years of treatment, I am still MRD negative – that means no cancer cells,' she said. 'I lost my husband to cancer. I have seen how hard it could be. 'My first thought after my diagnosis was, I will never see my grandchildren being born and growing up. 'Now I have two grandchildren, Drew and Alaia, and they are a delight and highlight the joys of a healthy life'. Ms Whitfield added: 'The way this trial was explained, it just made sense. Also, the thought of chemotherapy was scary to me. The trial felt right. And it was.' Many people who have chronic lymphocytic leukaemia do not have any symptoms, but the main ones include: swollen glands, usually in your neck or under your arms losing weight getting ill a lot feeling tired even though you've had a good night's sleep a rash that looks like small bruises or bleeding under the skin and does not fade when you roll a glass over it, similar to meningitis bleeding or bruising for no reason looking unusually pale and feeling breathless a high temperature even though you're not unwell aches and pains that will not go away sweating at night Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, which funded the trial along with AbbVie, and Johnson and Johnson, said: 'The results of the Flair trial show that we can provide kinder, more targeted treatment for chronic lymphocytic leukaemia, which gives people with CLL more precious time with their loved ones. 'We're hopeful that the results of the Flair trial will power new treatment options for leukaemia and other blood cancers, thanks to the efforts of researchers at in Leeds and across the UK working together on this trial.'
Yahoo
2 hours ago
- Yahoo
Signing up for clinical trials to be new feature on NHS App
Browsing and signing up to clinical trials will become a new feature on the NHS App as part of the Government's healthcare plan. Eventually the app will automatically match patients with studies based on their own interests and health data – and send push notifications with relevant new trials, the Department for Health and Social Care (DHSC) said. The NIHR's (National Institute for Health and Care Research) Be Part of Research service on the app is part of the Government's 10-year health plan. It takes around 100 days to set up a trial in Spain, but approximately 250 days in the NHS, DHSC said. The department projected the plan will see commercial trial set-up times fall to 150 by March 2026, which it described as 'the most ambitious reduction in trial set-up times in British history'. Health Secretary Wes Streeting said: 'The 10-year plan for health will marry the genius of our country's leading scientific minds, with the care and compassion of our health service, to put NHS patients at the front of the queue for new cutting-edge treatments. 'The NHS App will become the digital front door to the NHS, and enable all of us as citizens to play our part in developing the medicines of the future.' He added: 'The British people showed they were willing to be part of finding the vaccine for Covid, so why not do it again to cure cancer and dementia? 'By slashing through red tape and making it easier for patients to take part, reforms in our 10-year plan will grow our life sciences sector, generate news funds for the NHS to reinvest in frontline care, and benefit patients through better medicines.' The number of trials sponsored by commercial and non-commercial entities at specific NHS trusts, as well as organisations including universities, will be made public. This will reveal which are 'performing well and which are falling behind', DHSC added. Funding for NHS trusts will be prioritised for those who perform the best, DHSC said. The app announcement comes as the NIHR launches a UK-wide clinical trials recruitment drive. Studies are 'too slow' to set up in the UK because of 'unnecessary bureaucracy and duplication of activities across different agencies and sites', DHSC said. Researchers must currently agree separate contracts with each relevant area of the NHS, but the Government has pledged to introduce a 'national standardised contract'. Professor Lucy Chappell, chief scientific adviser at DHSC and chief executive of the NIHR, said: 'Ensuring all sites are consistently meeting the 150-day or less set-up time will bring us to the starting line, but together we aim to go further, faster to ensure the UK is a global destination for clinical research to improve the health and wealth of the nation.' The global clinical trials market is estimated to be worth at least 80 billion dollars (around £59 billion) by 2030, said Professor Andrew Morris, president of the Academy of Medical Sciences, which is a fellowship of leading scientists. Those who are under-represented – including young, black and South Asian people – are particularly encouraged to register for trials, DHSC said. Professor Morris added that the app will 'accelerate the translation of cutting-edge treatments from laboratory to bedside' and that making research accessible to all communities can help 'ensure that medical innovation benefits reach every corner of society.' 'The focus on improving participation from under-represented communities is important, though success will depend on earning trust and addressing the broader barriers to diverse participation', he said. Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, welcomed the initiative and said it could 'really increase the number and diversity of people taking part in critically-important dementia research'. 'With a growing pipeline of drugs for Alzheimer's disease currently in trials, it's vital programmes like this streamline recruitment so we can ensure these emerging treatments work for everyone,' he added.
